Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Dec 1;276(6):e1123-e1124.
doi: 10.1097/SLA.0000000000005405. Epub 2022 Feb 1.

Comment on: "Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis"

Stefan Boeck  1 , Volker Heinemann  1 , Jens Werner  2
Affiliations
Comment

Comment on: "Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis"

Stefan Boeck et al. Ann Surg. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Comment in

Comment on

  • Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis.
    Daamen LA, Groot VP, Besselink MG, Bosscha K, Busch OR, Cirkel GA, van Dam RM, Festen S, Groot Koerkamp B, Haj Mohammad N, van der Harst E, de Hingh IHJT, Intven MPW, Kazemier G, Los M, Meijer GJ, de Meijer VE, Nieuwenhuijs VB, Pranger BK, Raicu MG, Schreinemakers JMJ, Stommel MWJ, Verdonk RC, Verkooijen HM, Molenaar IQ, van Santvoort HC; Dutch Pancreatic Cancer Group. Daamen LA, et al. Ann Surg. 2022 Apr 1;275(4):769-775. doi: 10.1097/SLA.0000000000004093. Ann Surg. 2022. PMID: 32773631

References

    1. DaamenLAGrootVPBesselinkMG . Dutch Pancreatic Cancer Group. Detection, treatment, and survival of pancreatic cancer recurrence in the Netherlands: a nationwide analysis. Ann Surg. 2022;275:769–775.
    1. NeoptolemosJPPalmerDHGhanehP . European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capeci- tabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–1024.
    1. ConroyTHammelPHebbarM . Canadian Cancer Trials Group and the Unicancer-GI - PRO- DIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–2406.
    1. BjerregaardJKMortensenMBSchønnemannKR Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients. Eur J Cancer. 2013;49:98–105.
    1. BernardsNHaj MohammadNCreemersGJ Ten weeks to live: a population-based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands. Acta Oncol. 2015;54:403–410.

LinkOut - more resources